There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Accolade (ACCD – Research Report) and Sportradar Group AG Class A (SRAD – Research Report) with bullish sentiments. Accolade (ACCD) Morgan Stanley analyst Ricky Goldwasser maintained a Buy rating on Accolade yesterday and set a price target of $56.00. The company's shares closed last Monday at $36.76, close to its 52-week low of $32.87. According to TipRanks.com, Goldwasser is a 5-star analyst with an average return of 16.5% and a 65.8% success rate. Goldwasser covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Alignment Healthcare, and Bright Health Group. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Accolade with a $55.78 average price target, a 47.0% upside from current levels. In a report issued on September 30, Berenberg Bank also initiated coverage with a Buy rating on the stock with a $61.00 price target. See today’s analyst top recommended stocks >> Sportradar Group AG Class A (SRAD) In a report released yesterday, Thomas Allen from Morgan Stanley initiated coverage with a Buy rating on Sportradar Group AG Class A and a price target of $27.00. The company's shares closed last Monday at $22.58, close to its 52-week low of $22.00. According to TipRanks.com, Allen is a 5-star analyst with an average return of 19.1% and a 63.8% success rate. Allen covers the Services sector, focusing on stocks such as Membership Collective Group, Hilton Worldwide Holdings, and Marriott International. Sportradar Group AG Class A has an analyst consensus of Strong Buy, with a price target consensus of $29.45, a 25.5% upside from current levels. In a report released yesterday, Deutsche Bank also initiated coverage with a Buy rating on the stock with a $28.00 price target. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on ACCD: Analysts’ Opinions Are Mixed on These Services Stocks: Papa John’s International (PZZA) and Altice Usa (ATUS) Analysts’ Opinions Are Mixed on These Conglomerates Stocks: Aptiv (APTV) and Core Laboratories (CLB) Analysts Conflicted on These Financial Names: Landmark Infrastructure (LMRK), Essex Property (ESS) and AvalonBay (AVB) Analysts Offer Insights on Materials Companies: Albemarle (ALB) and Cemex SAB (CX) Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Merck & Company (MRK) and Protagonist Therapeutics (PTGX)